Chronic obstructive pulmonary disease (COPD) as syndrome of accelerated aging

Systemic manifestation and co-morbidity in chronic obstructive pulmonary disease (COPD) are associated with circulating markers of aging: a cross-sectional observational study with a longitudinal follow-up for two years

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN86049077

Enrollment

600

Registered

2010-05-18

Start date

2010-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease (COPD) Respiratory Other chronic obstructive pulmonary disease

Interventions

At baseline and 2 years later, the participants will be invited for two test days

one day at the Center of Expertise for Chronic Organ Failure (CIRO), Horn, and one day at the Maastricht University Medical Center (MUMC). For COPD patients, the test days will be planned before the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients: 1. Diagnosis of COPD according to the American Thoracic Society (ATS) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (forced expiratory volume in one second [FEV1] less than 80% predicted and FEV1/forced vital capacity [FVC] less than 70% and less than 10% predicted improvement in FEV1 after ?Ò2-agonist inhalation 2. Both male and female, aged from 50 to 75 years 3. No respiratory tract infection or exacerbation of the disease for less than 4 weeks before the study 4. Capable of providing informed consent Healthy subjects: 1. Healthy subjects as judged by a physician 2. Without diagnosed COPD or any other described co-morbidity/chronic disease 3. Both male and female, aged from 50 to 75 years

Exclusion criteria

Exclusion criteria: COPD patients: 1. Any kind of carcinogenic pathology less than 5 years before study participation 2. Participation in any other studies involving investigational or marketed products concomitantly or less than 4 weeks prior to entry into the study Healthy subjects: 1. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements 2. Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

Design outcomes

Primary

Measure	Time frame
All analysed at baseline: 1. Markers of aging 2. Objective diagnosed co-morbidity 3. Circulating hepatokines	—

Secondary

Measure	Time frame
All analysed at baseline: 1. Markers of systemic inflammation and oxidative stress 2. Classic characterisation of COPD	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026